<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; line-break: after-white-space;" class="">Hi everyone:<div class=""><br class=""></div><div class="">There are lots of interesting tidbits in this piece about how far your work on the TRIPS waiver campaign has pushed the White House in recent weeks: that the NSC has reportedly had several meetings about it; that the waiver supported by many in the admin’s public health circles; that it’s also supported by the USAID circles for diplomatic reasons; and that USTR has begun organizing its own interagency meetings about it. <div class=""><br class=""></div><div class="">Unfortunately, all that info is all wrapped up in the latest racist inanity backing pharma monopolies on the issue. First, TRIPS waiver opponents argued that only the U.S. and EU are capable of producing “complex” vaccines. Now they’re arguing that we can’t let China cheat its way into vaccinating people ahead of the U.S. Next it’s gonna be, “Watch out, undeserving people of color are going to get vaccinated at your expense!” (In fact, there’s some of that in this op-ed already.) </div><div class=""><br class=""></div><div class="">The good news is they’re only pushing this bullshit because they know they don’t have a leg to stand on, and that our arguments are gaining traction. Keep pushing!</div><div class=""><div class=""><br class=""><div class=""><div class="">
Arthur Stamoulis<br class="">Citizens Trade Campaign<br class="">(202) 494-8826<br class=""><br class=""><br class=""><br class="">
</div>
<div style="margin: 0in;" class=""><b class=""><font face="Calibri-Bold" class=""><span style="font-style: normal; font-size: 14px;" class="">Washington Post</span></font><font face="Calibri, sans-serif" size="6" class=""><o:p class=""></o:p></font></b></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><b class=""><span style="font-size: 24pt;" class="">Opinion: The wrong way to fight vaccine nationalism<o:p class=""></o:p></span></b></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><span style="color: blue;" class=""><a href="https://www.washingtonpost.com/people/josh-rogin/" class="">Josh Rogin</a>, </span><span style="font-size: 11pt;" class="">Columnist</span></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">April 8, 2021 at 6:46 p.m. EDT<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">Americans will not be safe from covid-19 until the entire world is safe. That basic truth shows why vaccine nationalism is not only immoral but also counterproductive. But the simplest solutions are rarely the correct ones, and some countries are using the issue to advance their own strategic interests. The Biden administration must reject the effort by some nations to turn our shared crisis into their opportunity.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">As the inequities of vaccine distribution worldwide grow, a group of more than 50 developing countries led by India and South Africa<a href="https://www.devex.com/news/at-wto-a-battle-for-access-to-covid-19-vaccines-98787" class=""><span style="color: blue;" class=""> is pushing </span></a>the World Trade Organization to dissolve all international intellectual property protections for pandemic-related products, which would include vaccine research patents, manufacturing designs and technological know-how. The Trump administration rejected <a href="https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True" class=""><span style="color: blue;" class="">the proposal</span></a> to waive <a href="https://www.who.int/medicines/areas/policy/wto_trips/en/" class=""><span style="color: blue;" class="">the agreement</span></a> on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the pandemic when it was introduced in October.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">Now, hundreds of nongovernmental organizations and <a href="https://delauro.house.gov/media-center/press-releases/delauro-schakowsky-blumenauer-doggett-espaillat-levin-urge-biden" title="delauro.house.gov" class=""><span style="color: blue;" class="">dozens</span></a> of Democratic lawmakers <a href="https://mkus3lurbh3lbztg254fzode-wpengine.netdna-ssl.com/wp-content/uploads/COVIDTRIPSWaiverSignOnLetter_022621.pdf" class=""><span style="color: blue;" class="">are pushing</span></a> the Biden administration to support the proposal. But many warn the move would result in the United States handing over a generation of advanced research — much of it funded by the U.S. taxpayer — to our country’s greatest competitors, above all China.<o:p class=""></o:p></div><div class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">In Congress, there’s justified frustration with the United States’ failure to respond to China’s robust vaccine diplomacy, in which Beijing has conditioned vaccine offers to pandemic-stricken countries on their <a href="https://economictimes.indiatimes.com/news/international/world-news/after-an-initial-failure-how-china-is-now-winning-the-vaccine-diplomacy-in-latin-america/articleshow/81525837.cms?from=mdr" class=""><span style="color: blue;" class="">ignoring security concerns </span></a>over Chinese telecom companies or<a href="https://www.bbc.com/news/world-asia-56661303" class=""><span style="color: blue;" class="">abandoning diplomatic recognition</span></a> of Taiwan. There’s also a lot of anger at Big Pharma among progressives for profiting from the pandemic.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">“We are in a race against time, and unfortunately Big Pharma is standing in the way of speedily addressing this problem,” Rep. Jan Schakowsky (D-Ill.), who supports the effort to waive intellectual property protections, told me in an interview. “I think the real security issue is that while the United States balks in making sure that we help ourselves, that these adversaries will just jump right in.”<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">Schakowsky argued that alternative measures for helping poor countries manufacture vaccines are simply not moving fast enough to save lives and that the United States has a duty to respond. House Speaker Nancy Pelosi (D-Calif.) personally conveyed her support for the waiver to President Biden, Schakowsky said.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">But Big Pharma is just one piece of the puzzle. Countries such as India and South Africa have been trying to weaken WTO intellectual property protections for decades. The mRNA technology that underpins the Pfizer and Moderna vaccines was funded initially by the <a href="https://www.washingtonpost.com/national-security/how-a-secretive-pentagon-agency-seeded-the-ground-for-a-rapid-coronavirus-cure/2020/07/30/ad1853c4-c778-11ea-a9d3-74640f25b953_story.html?itid=lk_inline_manual_13" title="www.washingtonpost.com" class=""><span style="color: blue;" class="">Defense Advanced Research Projects Agency</span></a> and has national security implications.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">Inside the Biden administration, the National Security Council has already convened several meetings on the issue. The waiver is supported by many global health officials in the White House and at the U.S. Agency for International Development, who believe the United States’ international reputation is suffering from its perceived “America First” vaccine strategy.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">On Wednesday, U.S. Trade Representative Katherine Tai <a href="https://twitter.com/USTRSpox/status/1379883344654110727" class=""><span style="color: blue;" class="">spoke with</span></a> WTO Director General Ngozi Okonjo-Iweala about the waiver issue. USTR is convening its own interagency meetings on the issue, which many see as a move to reassert its jurisdiction over WTO matters.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">If and when this does get to Biden’s desk, he will also hear from national security officials who believe that waiving TRIPS would result in the forced transfer of national security-sensitive technology to China, a country that strives to dominate the biotechnology field as part of its <a href="https://multimedia.scmp.com/news/china/article/2167415/china-2025-biotech/index.html" class=""><span style="color: blue;" class="">Made in China 2025 strategy</span></a>. Once countries such as China have this technology, they will apply their mercantilist industrial models to ensure their companies dominate these strategically important industries, potentially erasing thousands of U.S. jobs.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">“We would be delivering a competitive advantage to countries that are increasingly viewed as our adversaries, at taxpayer expense, when there are other ways of doing this,” said Mark Cohen, senior fellow at the University of California at Berkeley Law School.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">A preferable approach would be to build more vaccine-manufacturing capacity in the United States and then give those vaccines to countries in need, said Cohen. The U.S. pharmaceutical industry would surely benefit, but that’s preferable to being dependent on other countries when the next pandemic hits.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">“If there’s anything that the pandemic has taught us, it’s that we need to have a robust supply chain, for ourselves and for the world generally,” Cohen said.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">What’s more, it’s not clear that waiving the TRIPS agreement for the pandemic would work in the first place. Bill Gates and others involved in the current vaccine distribution scheme <a href="https://www.nytimes.com/2021/02/15/opinion/sway-kara-swisher-bill-gates.html?showTranscript=1" class=""><span style="color: blue;" class="">have argued</span></a> that it would not result in more vaccines, pointing out that licensing agreements are already successfully facilitating cooperation between patent-holding vaccine-makers and foreign manufacturers. Critics respond that such cooperation is still failing to meet the urgent needs in the developing world.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><br class=""></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class="">Vaccine equity is a real problem, but waiving intellectual property rights is not the solution. If the current system is not getting shots into the arms of people in poor countries, we must fix that for their sake and ours. But the pandemic and our responses to it have geopolitical implications, whether we like it or not. That means helping the world and thinking about our strategic interests at the same time.<o:p class=""></o:p></div><div style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;" class=""><span style="font-size: 12pt; font-family: "Times New Roman", serif;" class=""> </span></div></div></div></div></div></body></html>